Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 11/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 11/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 11/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.73 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.68 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8808892 | 0.87 | CYP1A1 (0.77) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL8808900 | 0.87 | CYP1A1 (0.77) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL17233466 | 0.85 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL7169376 | 0.85 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL18551884 | 0.84 | ABCG2 (0.81) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| 3',4'-Dimethoxychalcone SCHEMBL12485314 | 0.84 | TNFRSF1A (1.00) | CYP1A1CYP1A2CYP1B1TNFRSF1AABCB1 | |
| 3',4'-Dimethoxychalcone SCHEMBL12485318 | 0.84 | TNFRSF1A (1.00) | CYP1A1CYP1A2CYP1B1TNFRSF1AABCB1 | |
| SCHEMBL17233306 | 0.84 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL9475860 | 0.83 | CYP1B1 (1.00) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL9475867 | 0.83 | CYP1B1 (1.00) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015166043-A1 | COMPOUNDS | DE MONTFORT UNIVERSITY (GB) | 2015-11-05 | — | — | WO | disclosed |
| US-20030235889-A1 | Materials and methods involving conditional retention domains | ARIAD GENE THERAPEUTICS, INC. | 2003-12-25 | — | — | US | disclosed |
| US-6566073-B1 | Induction of preferential protein in cells; obtain genetically engineered cell, incubate with ligand and monitor expression of preferential protein | ARIAD GENE THERAPEUTICS, INC. | 2003-05-20 | — | — | US | disclosed |
| EP-1123405-A1 | MATERIALS AND METHODS INVOLVING CONDITIONAL AGGREGATION DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023600-A1 | MATERIALS AND METHODS INVOLVING CONDITIONAL AGGREGATION DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030235889-A1 | Materials and methods involving conditional retention domains | KDELR1, KDELR2, CD2BP2 | CYP1A1 4863/4885CYP1A2 4878/4885CYP1B1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.